|
[1]
|
Reactive metabolite of trovafloxacin activates inflammasomes: Implications for trovafloxacin‐induced liver injury
Journal of Applied Toxicology,
2024
DOI:10.1002/jat.4585
|
|
|
|
|
[2]
|
Reactive metabolite of trovafloxacin activates inflammasomes: Implications for trovafloxacin‐induced liver injury
Journal of Applied Toxicology,
2024
DOI:10.1002/jat.4585
|
|
|
|
|
[3]
|
Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?
Pharmaceutics,
2023
DOI:10.3390/pharmaceutics15030804
|
|
|
|
|
[4]
|
What Is Uncommon Can Be Critical: A Case of Quinolone-Induced Acute Liver Failure
Cureus,
2021
DOI:10.7759/cureus.14780
|
|
|
|
|
[5]
|
Norfloxacin Induced Recurrent Fixed Drug Eruption in a self Treated Adult Female Patient - A Case Report
Current Drug Safety,
2019
DOI:10.2174/1574886313666180807095559
|
|
|
|
|
[6]
|
Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
Pharmaceutical Research,
2018
DOI:10.1007/s11095-018-2497-z
|
|
|
|
|
[7]
|
Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016
Pharmacology Research & Perspectives,
2017
DOI:10.1002/prp2.297
|
|
|
|
|
[8]
|
A study of the efficacy and safety of new cephalosporin in the treatment of acute bacterial rhinosinusitis
Vestnik otorinolaringologii,
2016
DOI:10.17116/otorino201681673-77
|
|
|
|